GPx-1 polymorphism (rs1050450) contributes to tumor susceptibility: evidence from meta-analysis.

PURPOSE

Accumulating evidences implicate the selenium-containing cytosolic glutathione peroxidase, GPx-1, as a determinant of cancer risk and a mediator of the chemopreventive properties of selenium. Since the identification of a well-characterized functional polymorphism named Pro198Leu (rs1050450 C>T) in GPx-1, abundant studies have evaluated the association between Pro198Leu polymorphism and tumor risk in diverse population. But, the available results are conflicting.

METHODS

To derive a more precise estimation, we performed a meta-analysis based on 14,372 cases with different tumor types and 18,081 controls from 31 published case-control studies. Published literature from PubMed was retrieved. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of the association.

RESULTS

Overall, the results indicated that individuals who carried variant Leu allele (Pro/Leu and Leu/Leu) were associated with an increased cancer risk [odds ratio (OR) = 1.12, 95% confidence interval (CI) = 1.02-1.23] in a dominant genetic model. In further subgroup analyses, the increased risk of cancer was observed in subgroup of Asians and sample size more than 500 subjects.

CONCLUSION

These results suggest that the GPx-1 Pro198Leo polymorphism contributes to cancer susceptibility through a disturbed antioxidant balance.